PFIZER CONFIRMS U.S. PATENT TERM EXTENSION FOR IBRANCE UNTIL MARCH 2027
The Pharma Data
FEBRUARY 8, 2021
IBRANCE may impair fertility in males and has the potential to cause genotoxicity. Advise women not to breastfeed during IBRANCE treatment and for 3 weeks after the last dose because of the potential for serious adverse reactions in nursing infants. Advise male patients to consider sperm preservation before taking IBRANCE.
52 
Let's personalize your content